← Back to headlines
Vir Biotechnology Secures $1.7B Deal with Astellas for Prostate Cancer Asset
Vir Biotechnology's stock surged following the announcement of a deal worth up to $1.7 billion with Astellas to advance a prostate cancer asset.
23 Feb, 22:39 — 23 Feb, 22:39
ℹOnly 1 source covers this story
